Literature DB >> 17293108

1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism.

Thomas K Barthel1, Douglas R Mathern, G Kerr Whitfield, Carol A Haussler, H Andrew Hopper, Jui-Cheng Hsieh, Stephanie A Slater, Grace Hsieh, Magdalena Kaczmarska, Peter W Jurutka, Olga I Kolek, Fayez K Ghishan, Mark R Haussler.   

Abstract

1,25-Dihydroxyvitamin D(3) (1,25D) is known primarily as a regulator of calcium, but 1,25D also promotes phosphate absorption from intestine, reabsorption from kidney, and bone mineral resorption. FGF23 is a newly discovered phosphaturic hormone that, like PTH, lowers serum phosphate by inhibiting renal reabsorption via Npt2a. We show that 1,25D strongly upregulates FGF23 in bone. FGF23 then represses 1alpha-OHase activity in kidney, thus preventing spiraling induction of FGF23 by 1,25D. We also report that LRP5, Runx2, TRPV6, and Npt2c, all anabolic toward bone, and RANKL, which is catabolic, are transcriptionally regulated by 1,25D. This coordinated regulation together with that of FGF23 and PTH allows 1,25D to play a central role in maintaining calcium and phosphate homeostasis and bone metabolism. In the cases of LRP5, Runx2, TRPV6, and Npt2c we show that transcriptional regulation results at least in part from direct binding of VDR near the relevant gene promoter. Finally, because 1,25D induces FGF23, and FGF23 in turn represses 1,25D synthesis, a reciprocal relationship is established with FGF23 indirectly curtailing 1,25D-mediated intestinal absorption and counterbalancing renal reabsorption of phosphate. This newly revealed FGF23/1,25D/Pi axis is comparable in significance to phosphate and bone metabolism as the PTH/1,25D/Ca axis is to calcium homeostasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17293108     DOI: 10.1016/j.jsbmb.2006.12.054

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  57 in total

Review 1.  The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis.

Authors:  Mark R Haussler; G Kerr Whitfield; Ichiro Kaneko; Ryan Forster; Rimpi Saini; Jui-Cheng Hsieh; Carol A Haussler; Peter W Jurutka
Journal:  Rev Endocr Metab Disord       Date:  2012-03       Impact factor: 6.514

Review 2.  Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.

Authors:  Chiara Degirolamo; Carlo Sabbà; Antonio Moschetta
Journal:  Nat Rev Drug Discov       Date:  2015-11-16       Impact factor: 84.694

Review 3.  The rachitic tooth.

Authors:  Brian L Foster; Francisco H Nociti; Martha J Somerman
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

4.  The Pas de Trois of Vitamin D, FGF23, and PTH.

Authors:  Tally Naveh-Many; Justin Silver
Journal:  J Am Soc Nephrol       Date:  2016-11-02       Impact factor: 10.121

Review 5.  Vitamin D: Musculoskeletal health.

Authors:  Harjit Pal Bhattoa; Jerzy Konstantynowicz; Natalia Laszcz; Marek Wojcik; Pawel Pludowski
Journal:  Rev Endocr Metab Disord       Date:  2017-09       Impact factor: 6.514

Review 6.  Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.

Authors:  Katherine Wesseling-Perry; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2013-02-05       Impact factor: 3.714

Review 7.  Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism.

Authors:  Ming Chang Hu; Kazuhiro Shiizaki; Makoto Kuro-o; Orson W Moe
Journal:  Annu Rev Physiol       Date:  2013       Impact factor: 19.318

Review 8.  Nuclear receptors in bone physiology and diseases.

Authors:  Yuuki Imai; Min-Young Youn; Kazuki Inoue; Ichiro Takada; Alexander Kouzmenko; Shigeaki Kato
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

9.  1alpha,25-dihydroxyvitamin D3 acts predominately in mature osteoblasts under conditions of high extracellular phosphate to increase fibroblast growth factor 23 production in vitro.

Authors:  Ryoko Yamamoto; Tomoko Minamizaki; Yuji Yoshiko; Hirotaka Yoshioka; Kazuo Tanne; Jane E Aubin; Norihiko Maeda
Journal:  J Endocrinol       Date:  2010-06-08       Impact factor: 4.286

Review 10.  FGF-23 in bone biology.

Authors:  Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2009-12-15       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.